Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Xvivo Perfusion AB ( (SE:XVIVO) ) has shared an announcement.
XVIVO Perfusion AB announced that CEO Christoffer Rosenblad has been invited to present at J.P. Morgan’s 44th Annual Healthcare Conference in San Francisco on January 14, 2026, where he will also participate in a Q&A session. His presentation will address the future of the organ transplant industry and highlight how new technologies, including XVIVO’s Heart Assist Transport system currently in U.S. clinical trials, are expanding access to donor organs and improving organ utilization, underscoring the company’s efforts to position itself at the forefront of advanced organ preservation solutions.
The most recent analyst rating on (SE:XVIVO) stock is a Hold with a SEK189.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.
More about Xvivo Perfusion AB
XVIVO Perfusion AB is a Swedish medical technology company founded in 1998 and focused exclusively on extending the life of all major organs to enable more successful transplants. Headquartered in Gothenburg and listed on Nasdaq Stockholm under the ticker XVIVO, the company develops solutions that support transplant teams and researchers worldwide, with offices and research sites across two continents.
Average Trading Volume: 152,710
Technical Sentiment Signal: Sell
Current Market Cap: SEK5.51B
For an in-depth examination of XVIVO stock, go to TipRanks’ Overview page.